Age-2 aptamer
AssigneeKurume University
InventorsHiroyoshi Inoue, Yuichiro Higashimoto, Masayoshi Takeuchi, Shoichi Yamagashi
Life of this patent
Estimating the term…
Abstract
An AGE-2 aptamer which binds to a glyceraldehyde-derived advanced glycation end product (AGE-2) but not to human serum albumin and comprises at least 35 bases and in which the cytosine content in the bases is at least 35%, or the guanine content in the bases is at least 32%. Since the AGE-2 aptamer can be used for detecting AGE-2, it can be used as a reagent for detection/diagnosis, and an agent for prevention/treatment of AGE-2 involved diseases such as: diabetic complications such as diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy; neurodegenerative diseases such as Alzheimer's disease; and proliferation, metastasis, and invasion of malignant tumors.
Claims18
An aptamer that binds to a glyceraldehyde-derived advanced glycation end product (AGE-2), but does not bind to human serum albumin,
- wherein the aptamer comprises at least 35 bases, and
- the cytosine content in the bases is at least 35%, or the guanine content in the bases is at least 32%.
Dependencies are inferred from the claim text.